COVID-19 disruption to oncology practices and patients

As a service to our biotech and pharmaceutical manufacturing clients, MME conducted an online survey last month to assess COVID-19’s impact on practice dynamics and patient treatment options for independent and hospital-affiliated oncology practices.

The survey leveraged the insight of 51 oncologists from our vendor panel to evaluate effects from COVID-19 precautions. The following topics were discussed:

  • impact on practice dynamics
  • impact on practice’s participation in clinical trials
  • impact on practice’s revenues

The result of this study highlight key factors affecting the market including:

  • Nearly 80% of physicians reported moderate to severe disruptions. Impacts included: decreases in patient volume, absenteeism of staff (physicians, nurses, admin), delivery issues related to lab supplies. Issues affecting masks and gloves were reported to be the most disruptive.
  • Around 70% of physicians reported an increase in the use of telemedicine for phone consultations and appointment rescheduling.
  • 52% of physicians reported using an alternative site such as a home or outpatient hospital to provide active therapy.
  • Practices reported that 46% of their clinical trials have been paused or discontinued due to the pandemic.
  • On average, physicians estimate practices to continue to operate for six to seven months if pandemic dynamics continue.

As oncology practices adapt to the post-COVID-19 climate, developing grounded assumptions for changes to practice patterns will be critical for understanding PRMA implications.  Schedule a virtual meeting to discuss these results and evaluate the implications for your product.


Share on facebook
Share on twitter
Share on linkedin
Share on email

More News

let's talk!

Medical Marketing Economics

1200 Jefferson Ave.
Suite 200
Oxford, MS 38655

Medical Marketing Economics

8 Hillside Ave
Suite 301
Montclair, NJ 07042